Atai Life Sciences N.V.

ATAI
$3.81 (-3.54%)
08:00 PM UTC · Jun 08 · NASDAQ
#104 Bitcoin Treasuries

Atai Life Sciences N.V.

ATAI
#104 in Bitcoin Treasuries
Bitcoin Treasury Stock · NASDAQ · Berlin, DE
$3.81 (-3.54%)
08:00 PM UTC · Jun 08, 2026
BTC Holdings
58 BTC Treasury
Treasury Value
$3.67M
Sats per Share
29.25
mNAV
382.18x
Market Cap
$1.4B
Enterprise Value
$1.36B

Market Overview

Market Cap
Shares Outstanding
50-Day Moving Average
200-Day Moving Average
Average Volume (20 Days)
Beta (5Y)
  • Chart chart view
  • Table table view
  • Price
  • Market Cap MCap
  • Shares
Start Date
start date
to
End Date
start date
Date OPEN HIGH LOW CLOSE VWAP VOLUME %CHG $CHG
1D
5D
1M
3M
6M
YTD
1Y
5Y

Atai Life Sciences N.V. Company Overview

atai Beckley N.V. (NASDAQ: ATAI), formerly Atai Life Sciences N.V., is a clinical-stage biopharmaceutical company headquartered in Berlin, Germany, focused on developing therapeutic candidates for treatment-resistant depression, opioid use disorder, schizophrenia-related cognitive impairment, and other mental-health disorders. The company's lead asset BPL-003 (intranasal mebufotenin) recently produced rapid and durable antidepressant efficacy in a Phase 2a trial, 66.7% MADRS-50 response by Day 2, and was added to S&P Total Market and CRSP U.S. benchmark indices tracked by passive funds managing over $3 trillion. atai Beckley holds Bitcoin on its corporate balance sheet.

Atai Life Sciences N.V. website url Visit Website Atai Life Sciences N.V. linkedin url Atai Life Sciences N.V. twitter url
Stock Exchange NASDAQ
IPO Date 2021-06-18
Number of Employees 99
Headquarters Berlin, DE

Key Executives

Gerd G. Kochendoerfer

Chief Operating Officer
Gerd G. Kochendoerfer linkedin Gerd G. Kochendoerfer twitter

Glenn Short

Chief Scientific Officer
Glenn Short linkedin Glenn Short twitter

Jason Awe

Vice President of Investor Relations
Jason Awe linkedin Jason Awe twitter

Kevin Craig

Chief Medical Officer
Kevin Craig linkedin Kevin Craig twitter

Robert Conley

Chief Research & Development Officer
Robert Conley linkedin Robert Conley twitter

Srinivas G. Rao

Co-Founder, Chief Executive Officer & Executive Director
Srinivas G. Rao linkedin Srinivas G. Rao twitter

Christian Angermayer

Co-Founder & Chairman of the Board
Christian Angermayer linkedin Christian Angermayer twitter

Michael Eric Faerm

Chief Financial Officer
Michael Eric Faerm linkedin Michael Eric Faerm twitter

Anne Johnson

Chief Accounting Officer
Anne Johnson linkedin Anne Johnson twitter

Kavita Panke

Senior Vice President of New Product, Planning & Commercial
Kavita Panke linkedin Kavita Panke twitter

Ryan Barrett

Chief Legal & Business Officer
Ryan Barrett linkedin Ryan Barrett twitter

Featured Posts

View all articles

Press Releases

No press releases found.

Unlock Multi-Year Historical Data & Advanced Metrics
Professional subscribers get exclusive access to advanced data and tools designed to give them an edge in the market.
Multi-year historical data Data source URLs Custom index builder AI quarterly summaries Search & filter tools
View Plans — $29/mo

SEC Filings

Form Type Filed Accepted Source

Earnings Call Summaries

ATAI Frequently Asked Questions

The next earnings report date for Atai Life Sciences N.V. (ATAI) is scheduled for August 13, 2026. Stay up to date with ’s financial results and key announcements by visiting our Earnings Tracker or by subscribing to earnings alerts. Here we also provide ATAI earnings call summaries and transcripts.

As of March 31, 2025, Atai Life Sciences N.V. holds approximately 58 BTC as part of its corporate Bitcoin treasury strategy. For more comprehensive insights, you can track ATAI 's Bitcoin holdings on our Bitcoin Treasuries page.

The current stock price of Atai Life Sciences N.V. (ATAI) is $3.81 as of 08:00 PM UTC · Jun 08, 2026 . For live stock updates and company rankings, view our Bitcoin mining stocks by market cap table.

The latest news for Atai Life Sciences N.V. (ATAI) includes AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs published on April 8, 2026 . For more details and ongoing updates, visit the ATAI news section.